High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascadeMichael K. Kießling, Reinhard Dummer|Blood|2011Cited by 77
Mutant HRAS as novel target for MEK and mTOR inhibitorsMichael K. Kießling, Gerhard Rogler|Oncotarget|2015Cited by 59
Targeting the mTOR Complex by Everolimus in NRAS Mutant NeuroblastomaMichael K. Kießling, Gerhard Rogler|PLoS ONE|2016Cited by 35